CDK6

Across TCGA pan-cancer cohorts, CDK6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CDK6 data layer compared with 30 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CDK6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CDK6 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, UCEC, and LUAD are the cancer types where CDK6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.472	0.289	.012	12	view →
UCEC	OS	Tertile	III,IV	0.345	1.000	.018	8	view →
LUAD	OS	Median	III,IV	0.223	0.670	.011	6	view →
HNSC	DFS	Quartile	III,IV	0.493	0.762	.033	3	view →
GBM	DFS	Tertile	All	0.243	0.507	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CDK6–PDAC (DFS)

Open the PDAC breakdown →